Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study

被引：21
作者：
Marta Sardà Sánchez
Joan Calzada Hernández
Susanna Hernández-Bou
Gemma Claret Teruel
Jesús Velasco Rodríguez
Carles Luaces Cubells
机构：
[1] Emergency Department, Hospital Sant Joan de Déu, Universitat de Barcelona, 08950, Esplugues de Llobregat, Barcelona
[2] Laboratory Department, Hospital Sant Joan de Déu, Universitat de Barcelona, 08950, Esplugues de Llobregat, Barcelona
来源：
BMC Research Notes | / 5卷 / 1期
关键词：
Children; Pneumonia; Pro-adrenomedullin;
D O I：
10.1186/1756-0500-5-363
中图分类号：
学科分类号：
摘要：
Background: In adult population with community acquired pneumonia high levels of pro-adrenomedullin (pro-ADM) have been shown to be predictors of worse prognosis. The role of this biomarker in pediatric patients had not been analyzed to date. The objective of this study is to know the levels of pro-ADM in children with community acquired pneumonia (CAP) and analyze the relation between these levels and the patients' prognosis. Findings: Prospective observational study including patients attended in the emergency service (January to October 2009) admitted to hospital with CAP and no complications at admission. The values for pro-ADM were analyzed in relation to: need for oxygen therapy, duration of oxygen therapy, fever and antibiotic therapy, complications, admission to the intensive care unit, and length of hospital stay. Fifty patients were included. Ten presented complications (7 pleural effusion). The median level of pro-ADM was 1.0065 nmol/L (range 0.3715 to 7.2840 nmol/L). The patients presenting complications had higher levels of pro-ADM (2.3190 vs. 1.1758 nmol/L, p = 0.013). Specifically, the presence of pleural effusion was associated with higher levels of pro-ADM (2.9440 vs. 1.1373 nmol/L, p 0.001). Conclusions: In our sample of patients admitted to hospital with CAP, pro-ADM levels are related to the development of complications during hospitalization. © 2012 Sardà Sánchez et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 13 条
[1]  
Querol-Ribelles J.M., Tenias J.M., Querol-Borras J.M., Gonzalez-Granda D., Hernandez M., Ferreruela R., Martinez I., Validación del Pneumonia Severity Index en la hospitalizació n de los pacientes con neumonía adquirida en la comunidad, Medicina Clinica, 122, 13, pp. 481-486, (2004)
[2]  
Bauer T.T., Ewig S., Marre R., Suttorp N., Welte T., CRB-65 predicts death from community-acquired pneumonia, Journal of Internal Medicine, 260, 1, pp. 93-101, (2006)
[3]  
Almirall J., Bolibar I., Toran P., Pera G., Boquet X., Balanzo X., Sauca G., Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia, Chest, 125, 4, pp. 1335-1342, (2004)
[4]  
Masia M., Gutierrez F., Shum C., Padilla S., Navarro J.C., Flores E., Hernandez I., Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index, Chest, 128, 4, pp. 2223-2229, (2005)
[5]  
Yende S., Tuomanen E.I., Wunderink R., Kanaya A., Newman A.B., Harris T., De Rekeneire N., Kritchevsky S.B., Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia, American Journal of Respiratory and Critical Care Medicine, 172, 11, pp. 1440-1446, (2005)
[6]  
Christ-Crain M., Morgenthaler N.G., Stolz D., Muller C., Bingisser R., Harbarth S., Tamm M., Struck J., Bergmann A., Muller B., Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397], Critical Care, 10, 3, (2006)
[7]  
Huang D.T., Angus D.C., Kellum J.A., Pugh N.A., Weissfeld L.A., Struck J., Delude R.L., Rosengart M.R., Yealy D.M., Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia, Chest, 136, pp. 823-831, (2009)
[8]  
Christ-Crain M., Morgenthaler N.G., Struck J., Harbarth S., Bergmann A., Muller B., Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: An observational study, Crit Care, 9, pp. 18816-18824, (2005)
[9]  
Gegenhuber A., Struck J., Dieplinger B., Poelz W., Pacher R., Morgenthaler N.G., Bergmann A., Haltmayer M., Mueller T., Comparative Evaluation of B-Type Natriuretic Peptide, Mid-Regional Pro-A-type Natriuretic Peptide, Mid-Regional Pro-Adrenomedullin, and Copeptin to Predict 1-Year Mortality in Patients With Acute Destabilized Heart Failure, Journal of Cardiac Failure, 13, 1, pp. 42-49, (2007)
[10]  
Hirata Y., Mitaka C., Sato K., Nagura T., Tsunoda Y., Amaha K., Marumo F., Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis, Journal of Clinical Endocrinology and Metabolism, 81, 4, pp. 1449-1453, (1996)
12